Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will
present three posters highlighting data for XMT-1660, XMT-2056, and
the Immunosynthen ADC platform at the upcoming American Association
for Cancer Research (AACR) Annual Meeting 2022 to be held in New
Orleans, Louisiana from April 8-13, 2022.
“ADC innovation is at the core of Mersana’s strategy, and we
have made significant progress in building out an innovative
pipeline of potential cancer medicines. Our preclinical data show
the potential of XMT-1660 in a range of B7-H4 expressing tumors and
the power of our Dolasynthen platform,” said Anna Protopapas,
President and Chief Executive Officer of Mersana Therapeutics. “The
preclinical profile of XMT-2056 as monotherapy and in combination
with standard of care therapies in both HER2-high and HER2-low
expressing models reinforces the differentiation of the
Immunosynthen platform. We look forward to advancing both molecules
into the clinic in mid-2022.”
XMT-1660 is a Dolasynthen ADC targeting B7-H4, a target
selectively expressed on tumors in areas of high unmet medical
need, including breast, endometrial, ovarian and other cancers. The
data show that a single dose of XMT-1660 has anti-tumor activity in
both triple-negative breast cancer (TNBC) and estrogen receptor
(ER)-positive breast cancer xenograph models. Higher B7-H4
expression is associated with greater anti-tumor activity of
XMT-1660 in preclinical studies. Mersana expects a Phase 1 clinical
trial for XMT-1660 to start in mid-2022.
XMT-2056, Mersana’s first Immunosynthen STING-agonist ADC,
targets a novel epitope of HER2, and is designed to offer a
differentiated and complementary therapeutic approach to the
treatment of HER2-expressing tumors. The preclinical data presented
show that XMT-2056 demonstrates robust anti-tumor activity as a
monotherapy in both HER2-high and HER2-low expressing models.
XMT-2056’s complementary mechanism of action results in increased
efficacy in combination with trastuzumab, pertuzumab, anti-PD-1, or
trastuzumab deruxtecan in preclinical studies. Mersana expects to
initiate a Phase 1 clinical trial of XMT-2056 in mid-2022.
Immunosynthen is Mersana’s immunostimulatory ADC platform
designed to take ADCs beyond traditional cytotoxic drugs to
targeted stimulation of the innate immune system. Data show that
anti-tumor activity of Immunosynthen STING-agonist ADCs involves
the targeted activation of the STING pathway in an antigen
binding-dependent manner in both tumor-resident immune cells and in
tumor cells. In addition to delivery to the tumor cell via antigen
binding and internalization, data from multiple models demonstrate
Fcγ-R1 is the major receptor that mediates delivery to a specific
population of myeloid cells resident in primary human tumors,
eliciting potent anti-tumor responses in preclinical studies.
Details of the presentations are as
follows:
Poster Title: Anti-tumor effect of XMT-1660, a
B7-H4 targeting antibody drug conjugate, in an unselected panel of
patient derived xenograft models of breast cancer Poster
Board Number: 8Session Category:
Experimental and Molecular TherapeuticsSession
Title: Antibody Drug Conjugates
Date/Time: Monday, April 11, 2022 at 1:30pm –
5:00pm CDT Location: New Orleans Convention
Center, Exhibit Halls D-H, Poster Section 21
Poster Title: XMT-2056, a HER2-targeted
Immunosynthen STING-agonist antibody-drug conjugate, binds a novel
epitope of HER2 and shows increased anti-tumor activity in
combination with trastuzumab and pertuzumab Poster Board
Number: 5Session Category: Immunology
Session Title: Immunomodulatory Agents and
Interventions 2 Date/Time: Tuesday, April 12, 2022
at 1:30pm – 5:00pm CDT Location: New Orleans
Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Title: Tumor cell-targeted STING-agonist
antibody-drug conjugates achieve potential anti-tumor activity by
delivering STING agonist specifically to tumor cells and
FcγRI-expressing subset of myeloid cells Poster Board
Number: 15Session Category: Immunology
Session Title: Innate Immunity to Cancer
Date/Time: Monday, April 11, 2022 at 1:30pm –
5:00pm CDT Location: New Orleans Convention
Center, Exhibit Halls D-H, Poster Section 40
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a
single-arm registrational trial in patients with platinum-resistant
ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial
evaluating UpRi in combination with other ovarian cancer therapies.
XMT-1592, Mersana’s second ADC product candidate targeting
NaPi2b-expressing tumors, was created using Mersana’s customizable
and homogeneous Dolasynthen platform and is in the dose exploration
portion of a Phase 1 clinical trial. The Company’s early-stage
programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as
well as XMT-2056, a STING-agonist ADC developed using the Company’s
Immunosynthen platform and targeting a novel epitope of HER2. In
addition, multiple partners are using Mersana’s platforms to
advance their ADC pipelines. Mersana was recently named among the
2021 Top Places to Work in Massachusetts by The Boston Globe.
Mersana routinely posts information that may be useful to investors
on the “Investors and Media” section of its website at
www.mersana.com.
Forward-Looking Statements
This press release contains “forward-looking” statements and
information within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as “aims,” “anticipates,” “believes,” “could,” “estimates,”
“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,”
“possible,” “potential,” “seeks,” “will” and variations of these
words or similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements
concerning the therapeutic potential of Mersana’s product
candidates, the potential of Mersana’s platforms and technology,
and Mersana’s anticipated initiation of Phase I clinical trials of
XMT-1660 and XMT-2056. Mersana may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including, among other things, uncertainties inherent in research
and development, in the initiation of clinical trials and in the
clinical development of Mersana’s product candidates; the risk that
Mersana’s anticipated clinical trials may not be initiated on
schedule, if at all; the risk that Mersana may not realize the
intended benefits of its platforms and technology; whether the
outcomes of preclinical studies will be predictive of clinical
trial results; risks to clinical trial site initiation, patient
enrollment and follow-up, as well as to Mersana’s abilities to meet
other anticipated deadlines and milestones, presented by the
ongoing COVID-19 pandemic; and other important factors, any of
which could cause Mersana’s actual results to differ from those
contained in the forward-looking statements, that are described in
greater detail in the section entitled “Risk Factors” in Mersana’s
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on February 28, 2022, as well as in other
filings Mersana may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Mersana expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether because of any new information, future events,
changed circumstances or otherwise, except as otherwise required by
law.
Contact:Investor & Media ContactJason
Fredette 617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024